OpenAI acquires Orchestra Bio

OpenAI announced it will acquire Orchestra Bio, a company that provides AI-driven tools for life‑science research. The acquisition aims to integrate AI‑powered operations into biopharma R&D, with the goal of speeding up drug development and supporting the creation of new therapies.

Summary written by Kernelia from the original article by OpenAI News. The story and its rights belong to its author.